ライフサイエンスコーパス: heart valve

1 ompared with a self-expandable transcatheter heart valve.

2 history of valvular repair in an unaffected heart valve.

3 f-expanding and repositionable transcatheter heart valve.

4 reduction of GAGs in tissues, urine, and the heart valve.

5 ommercially available SAPIEN 3 transcatheter heart valve.

6 neae, and a balloon-expandable transcatheter heart valve.

7 -generation balloon-expandable transcatheter heart valve.

8 bled S. lugdunensis to bind and colonize the heart valves.

9 bacteria-platelet aggregates on the injured heart valves.

10 uch as venous thromboembolism and mechanical heart valves.

11 " tissue engineered transcatheter homologous heart valves.

12 activating receptors in embryonic and larval heart valves.

13 icipated consequence of targeting developing heart valves.

14 se of dabigatran in patients with mechanical heart valves.

15 imitations of a new generation of prosthetic heart valves.

16 e +/-1 grade in both treatment groups at all heart valves.

17 vent or abolish biofilm formation on injured heart valves.

18 ly progressing, destructive infection of the heart valves.

19 e heart and later is expressed in developing heart valves.

20 answered questions for tissue engineering of heart valves.

21 ent paradigms for creating tissue-engineered heart valves.

22 formance of balloon-expandable transcatheter heart valves.

23 7-0.66), as did participants with mechanical heart valve (0.52, 0.35-0.77).

24 e TAVI using the EdwardsSAPIEN Transcatheter Heart Valve (23 mm, n=19; 26 mm, n=50; 29 mm, n=3).

25 compare them with 134 patients with a tissue heart valve and 2620 other patients without a prosthetic

26 p A streptococcal autoimmune sequelae of the heart valve and brain.

27 ciplinary team and substantial experience in heart valve and endovascular therapies.

28 he balloon-expandable SAPIEN 3 transcatheter heart valve and underwent CA with or without percutaneou

29 r matrix protein that is highly organized in heart valves and arteries.

30 s the mediators of calcification in diseased heart valves and atherosclerotic plaques.

31 colonizing medical implant devices, such as heart valves and catheters, where treatment of the infec

32 gulation therapy in patients with mechanical heart valves and critically evaluate current antithrombo

33 ndards required for manufacturing artificial heart valves and has superior mechanical, hemocompatibil

34 mended (class I) in patients with mechanical heart valves and in patients with atrial fibrillation wi

35 e endocardial cells overlying the developing heart valves and is dependent upon both hemodynamic shea

36 BCs) passing through heart pumps, prosthetic heart valves and other cardiovascular devices undergo ea

37 ed excellent durability of the transcatheter heart valves and SAVR.

38 ve procedure in the past 30 days, prosthetic heart valve, and higher number of positive blood culture

39 acteremia, community acquisition, prosthetic heart valve, and male sex are associated with increased

40 ey die perinatally with open eyes, misshapen heart valves, and growth plate defects.

41 r Sox9 is expressed in developing and mature heart valves, and its function is required for expressio

42 d homologous off-the-shelf tissue engineered heart valves are demonstrated in a relevant pre-clinical

43 The mature heart valves are dynamic structures composed of highly o

44 Because transcatheter heart valves are implanted in a sutureless fashion using

45 The mature heart valves are made up of highly organized extracellul

46 comparative data on different transcatheter heart valves are missing.

47 y because of the determination of prosthetic heart valve area [called effective orifice area index (E

48 First described in developing heart valves as an epithelial mesenchymal transformation

49 where they take up residence, in the case of heart valves, as valve interstitial cells.

50 initial transcriptomic analysis of postnatal heart valves at single cell resolution demonstrates that

51 Danish residents who received a replacement heart valve between 1989 and 2006.

52 are implanted surgically, and bioprosthetic heart valves (BHV), which can be implanted via a surgica

53 Bioprosthetic heart valves (BHVs) are commonly used as heart valve rep

54 m (BP) being the primary biomaterial used in heart valve bioprostheses, recipient graft-specific immu

55 ERalpha was expressed in developing heart valves but not in the liver, whereas ERbeta2 had t

56 ients with atrial fibrillation or mechanical heart valves, but effective management is complex, and t

57 complex with aggregated platelets on injured heart valves, but the host factors that interconnect and

58 oderate/severe mitral stenosis or mechanical heart valves, but variably included patients with other

59 hanistic links between ERE activation in the heart valves by BPA's reactive metabolite MBP and the de

60 llow a pathway analogous to that of surgical heart valves by incorporating OPC and provides several c

61 Surgical replacement of diseased heart valves by mechanical and tissue valve substitutes

62 des insight into the molecular mechanisms of heart valve calcification and identifies reduced Sox9 fu

63 In the United States, new surgical heart valves can be approved on the basis of objective p

64 Heart valve cells mediate extracellular matrix (ECM) rem

65 Single cell analysis of mouse heart valve cells was used to evaluate cell heterogeneit

66 ards CENTERA-EU Self-Expanding Transcatheter Heart Valve [CENTERA-2]; NCT02458560).

67 at concentrating experience in higher volume heart valve centers might be a means of improving outcom

68 surgical risk, were recruited at 20 tertiary heart valve centres in Germany, the Netherlands, Switzer

69 ar ejection fraction (>=50%) followed in the heart valve clinics of 4 high-volume centers.

70 ivity to phagocytic killing or efficiency of heart valve colonization.

71 in the development of tissue engineering of heart valves constructs by altering extracellular matrix

72 A tissue engineered heart valve could, in principle, accommodate these requi

73 rain (peri-ventricular nodular heterotopia), heart (valve defect), skeleton, gastrointestinal tract,

74 patient with Tetralogy of Fallot, a serious heart valve defect, affects the substrate selectivity of

75 e experience with the SAPIEN 3 transcatheter heart valve, dependent on patient consent, before the st

76 During embryogenesis the heart valves develop from undifferentiated mesenchymal e

77 cells direct the complex cellular process of heart valve development and suggest that congenital valv

78 owth factor (HB-EGF), a crucial regulator of heart valve development in mice.

79 hierarchies that control normal and abnormal heart valve development in parallel with other connectiv

80 Heart valve development is regulated by complex interact

81 Heart valve development proceeds through coordinated ste

82 tion and proliferation, the role of Tbx20 in heart valve development remains relatively unknown.

83 forces play an essential epigenetic role in heart valve development, but how they do so is not known

84 ay genes are differentially expressed during heart valve development.

85 oral and spatial expression of Nfatc1 during heart valve development.

86 rograms and mechanosensation interact during heart valve development.

87 s into mesenchymal cells, a critical step in heart valve development.

88 Properly controlled EndMT is essential for heart valve development: too little and valves fail to f

89 hanical forces are well known for modulating heart valve developmental programs.

90 n of ECM organization is a common feature of heart valve disease and can often be linked to genetic d

91 proportion of patients with previously known heart valve disease and diabetes mellitus significantly

92 ntial of anti-TNF drugs for the treatment of heart valve disease and identify potential therapeutic t

93 ese cells may be important for understanding heart valve disease and may also be applied to current p

94 rix remodeling genes characteristic of human heart valve disease are observed in juvenile scx(-/-) mi

95 d family members presenting with progressive heart valve disease early in life.

96 Heart valve disease is a common manifestation of cardiov

97 Heart valve disease is an important cause of morbidity a

98 lines, many patients with severe symptomatic heart valve disease might not undergo intervention.

99 n an individual basis, patients with organic heart valve disease who are trying to delay or avoid sur

100 nknown Origin of bacteremia, 4 points; prior heart Valve disease, 2 points; Auscultation of a heart m

101 persistent or recurrent fever, a history of heart valve disease, and S aureus as the causative patho

102 lopmental mechanisms are redeployed in adult heart valve disease, in cardiac fibrosis, and in myocard

103 Despite the high frequency of heart valve disease, only a handful of genes have so far

104 uring the operative management of left-sided heart valve disease, particularly in the setting of mitr

105 ound Mitral valve prolapse (MVP) is a common heart valve disease, the most frequent indication for va

106 stin-insufficient mice would manifest viable heart valve disease.

107 enfluramine (Fen), have been associated with heart valve disease.

108 he possibility of preventing the most common heart valve disease.

109 oma, atrial fibrillation, heart failure, and heart valve disease.

110 Willebrand factor (VWF) multimer profile and heart valve diseases (HVD).

111 Aortic stenosis is 1 of the most common heart valve diseases among adults.

112 diomyopathy, 83.5% (95% CI, 80.2%-86.8%) for heart valve disorder, 81.3% (95% CI, 77.6%-85.0%) for pu

113 %]), cardiac (any cardiac condition, such as heart valve disorders, 56.4% [95% CI, 53.5%-59.2%]), and

114 Anticoagulation for mechanical heart valves during pregnancy is essential to prevent th

115 tiveness of the Edwards SAPIEN transcatheter heart valve (Edwards Lifesciences LLC, Irvine, Californi

116 n=129) or a balloon-expandable transcatheter heart valve (Edwards SAPIEN 3, n=117).

117 e, N-acetyl-beta-D-glucosamine (GlcNAc), and heart valve endothelium, laminin and laminar basement me

118 s the Edwards SAPIEN/SAPIEN XT transcatheter heart valve (ESV) for severe aortic stenosis.

119 Two types of artificial heart valve exist: mechanical heart valves (MHV), which

120 The dock and transcatheter heart valve form an ensemble, with the native mitral val

121 Using a zebrafish model of defective heart valve formation caused by morpholino oligonucleoti

122 At the early stages of zebrafish heart valve formation, we show that endocardial cells ar

123 the endocardium during a critical window of heart valve formation.

124 e production and deposition of matrix at the heart-valve-forming region, resulting in the inability o

125 comes after TMVR with a mitral transcatheter heart valve (Fortis, Edwards Lifesciences, Irvine, Calif

126 on using 83 formalin-fixed paraffin-embedded heart valves from subjects with endocarditis who had pos

127 gress toward understanding the mechanisms of heart valve function and dysfunction.

128 nd other heart valves, which is essential to heart valve function.

129 mmarizes an evolving conceptual framework of heart valve functional structure, developmental biology,

130 to promote ectopic osteogenic phenotypes in heart valves has not been examined.

131 valve replacement using aortic transcatheter heart valves has recently become an alternative for pati

132 All prosthetic heart valves have some degree of VP-PM which must be pla

133 nfidence interval [CI], 1.6-8.0), prosthetic heart valve (HR, 6.2; 95% CI, 3.8-10.1), male sex (HR, 2

134 Heart valve (HV) replacements are among the most widely

135 Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low-Risk Patients With Aortic Stenosis) C

136 able versus balloon-expandable transcatheter heart valves in bicuspid aortic stenosis are lacking.

137 OICE (Randomized Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic St

138 by structural deterioration of transcatheter heart valves in only 5 patients.

139 expandable and self-expandable transcatheter heart valves in the treatment of bicuspid aortic stenosi

140 r the management of patients with prosthetic heart valves in these areas of controversy.

141 served following direct knockdown of Sox9 in heart valves in vitro.

142 y a field of cardiac progenitor cells as the heart-valve-inducing region amid developing atria and ve

143 ention of stroke in patients with mechanical heart valves, initial studies have been unfavorable for

144 d by mediating factors, including mechanical heart valve insertion, atrial fibrillation, and anticoag

145 xplained by an indirect effect of mechanical heart valve insertion, atrial fibrillation, or treatment

146 at activation of 5-HT(2B) receptors on human heart valve interstitial cells in vitro induces a prolif

147 Prosthetic heart valve interventions continue to evolve with new in

148 infancy, percutaneous valve therapies offer heart valve interventions without the use of cardiopulmo

149 disorder, but is frequently associated with heart valve involvement.

150 ith the repositionable Portico transcatheter heart valve is feasible, with good short-term clinical a

151 ement using the Edwards SAPIEN transcatheter heart valve is safe and effective in patients with dysfu

152 Development of the heart valves is a complex process that relies on the suc

153 sing aortic balloon-expandable transcatheter heart valves is associated with a low complication rate,

154 show that retinoic acid treatment in mature heart valves is sufficient to promote calcific processes

155 loped and validated in vivo against 15 sheep heart valves, later excised.

156 remodeling endocardial cushions into mature heart valve leaflets and is also an essential effector o

157 ;Col2a1-cre mice develop calcific lesions in heart valve leaflets associated with increased expressio

158 cur locally during embryonic development, at heart valve leaflets, and at sites of aneurysm formation

159 ;Col2a1-cre mice die at birth with thickened heart valve leaflets, reduced expression of cartilage-as

160 ients with Down syndrome have characteristic heart valve lesions resulting from endocardial cushion d

161 Heart valve lesions were found in 50% of the cases.

162 ne 2010 after reports of an association with heart valve lesions.

163 l organs, sinus lining cells in bone marrow, heart valves, ligaments and connective tissues.

164 Reduced lysosomal storage in heart valves, liver, and spleen provided evidence that i

165 network procuring organs such as the heart, heart valves, lung, liver, kidneys, cornea, and skin.

166 Heart valve malformations are one of the most common typ

167 evelopment, but its roles in later stages of heart valve maturation and homeostasis have not been ide

168 Such engineered heart valves may represent an interesting alternative to

169 f homologous off-the-shelf tissue engineered heart valves may therefore substantially simplify previo

170 Pregnant women with a mechanical heart valve (MHV) are at a heightened risk of a thrombot

171 of artificial heart valve exist: mechanical heart valves (MHV), which are implanted surgically, and

172 d collagen adhesion using an in vitro rabbit heart valve model, suggesting a role for the glycoconjug

173 The heart-valve myocardium expresses bone morphogenetic prot

174 asingly common cause of infections of native heart valves (native valve endocarditis [NVE]).

175 Risk factors for IE were prosthetic heart valve (odds ratio [OR]: 3.93; 95% CI: 1.76 to 8.77

176 Bacterial growth in cultures of resected heart valves of patients with infective endocarditis (IE

177 o were taking warfarin because of mechanical heart valves or atrial fibrillation and who were compete

178 We analysed patients with mechanical heart valves or atrial fibrillation separately.

179 many future applications, such as artificial heart valves or elastocaloric cooling, in which more tha

180 gonists activated the reporter in either the heart valves or the liver.

181 Obstructive thrombosed prosthetic heart valve (OTPHV) is a serious complication of heart v

182 compared with 79% of patients with a tissue heart valve (P<0.001) and 78% of patients without a pros

183 th an MHV, in 5.1% of patients with a tissue heart valve (P<0.001), and in 4.9% of patients without a

184 th an MHV, in 1.5% of patients with a tissue heart valve (P=1.000), and in 0.2% of patients without a

185 g abuse, rheumatic heart disease, prosthetic heart valves, pacemakers, or immunodeficiency.

186 ing evaluated in the clinical realm for each heart valve, particularly for the aortic and mitral posi

187 gurgitation (TR) often accompanies left-side heart valve pathology and does not always reverse with i

188 scopy are the main techniques for prosthetic heart valve (PHV) evaluation, but because of specific li

189 T/CT in patients with noninfected prosthetic heart valve (PHV).

190 Prosthetic heart valves (PHVs) that require aortic root replacement

191 nduce similar patterns of gene expression in heart valve precursor cells was examined.

192 As with any heart valve-preserving procedure, patient selection and

193 he use of a balloon-expandable transcatheter heart valve previously resulted in a greater rate of dev

194 539 consecutive patients with previous left heart valve procedure (time interval from valve procedur

195 tricuspid regurgitation (TR) late after left heart valve procedure is frequent and associated with in

196 the impact of significant TR late after left heart valve procedure.

197 tly associated with survival late after left heart valve procedure.

198 rt valves, to date, the clinically available heart valve prostheses for surgical and transcatheter re

199 Current heart valve prostheses have limitations that include dur

200 st common causes of infections of prosthetic heart valves (prosthetic valve endocarditis [PVE]) and a

201 tER Valve Trial Edwards SAPIEN Transcatheter Heart Valve) randomized trial (cohorts A and B) and acco

202 The heart valve recipients were matched with 95,481 unexpose

203 rs results in cell fate changes in which the heart-valve region adopts the identity of differentiated

204 The United Kingdom Heart Valve Registry was interrogated for 1962 first-tim

205 ) or pathologically (high blood pressure and heart-valve regurgitation).

206 enter study to compare the frequency of left heart valve regurgitations in diabetic patients exposed

207 ignificant increase in the frequency of left heart valve regurgitations in diabetic patients.

208 ve risk (odds ratio) of mild or greater left heart valve regurgitations were significantly increased

209 re was the frequency of mild or greater left heart valve regurgitations.

210 dds of dying within 30 days after colectomy, heart valve repair/replacement, or abdominal aortic aneu

211 italization; coronary artery bypass surgery; heart valve repair/replacement; percutaneous coronary in

212 Percutaneous heart valve replacement (PHVR) is an emerging, catheter-

213 Danish population-based cohort study, using heart valve replacement as an instrumental variable.

214 The authors used the heart valve replacement instrument to estimate rate rati

215 nsive overview of current clinically adopted heart valve replacement options, with a focus on transca

216 t valve (OTPHV) is a serious complication of heart valve replacement.

217 dysfunction, and after mechanical prosthetic heart valve replacement.

218 tic heart valves (BHVs) are commonly used as heart valve replacements but they are prone to fatigue f

219 The Sapien transcatheter heart valve represents an alternative device with simila

220 core laboratory-based study of transcatheter heart valves revealed excellent durability of the transc

221 T cells in peripheral blood and in rheumatic heart valves revealed the presence of T cells crossreact

222 ew balloon-expandable Sapien 3 transcatheter heart valve (S3-THV) incorporates new features to reduce

223 Polymeric heart valves seem to be an attractive alternative to mec

224 support shared decision making in prosthetic heart valve selection does not lower decisional conflict

225 e patient decision aid to support prosthetic heart valve selection was recently developed.

226 tion of shared decision making in prosthetic heart valve selection.

227 Those with prosthetic heart valves, significant mitral stenosis, and valvular

228 ECM collagen deficiency and impact on heart valve structural integrity were confirmed by histo

229 iews the evolving paradigm of a continuum of heart valve structure, function, and pathobiology and ex

230 high levels of scx expression in remodeling heart valve structures at embryonic day 15.5 through pos

231 Heart valve structures derived from mesenchymal cells of

232 cx(-/-) mice display significantly thickened heart valve structures from embryonic day 17.5, and valv

233 Calcification of heart valve structures is the most common form of valvul

234 Heart valve structures, derived from mesenchyme precurso

235 ressed into adulthood in the vasculature and heart valves, suggesting later roles in vascular develop

236 Timely heart valve surgery can mitigate the progression to hear

237 d is the second most frequent indication for heart valve surgery in Western countries.

238 spid annuloplasty is recommended during left-heart valve surgery when the tricuspid annulus (TA) is d

239 rgitation are done at the time of left-sided heart valve surgery.

240 lism, diabetics, cardiovascular disease, and heart valve surgery.

241 e procedural volume-outcome relationship for heart valve surgery.

242 ions during coronary-artery bypass grafting, heart-valve surgery, or both between June 30, 1998, and

243 t with either a self-expanding transcatheter heart valve (Symetis ACURATE neo, n=129) or a balloon-ex

244 e emphasize the value of a multidisciplinary heart valve team, the endocarditis team, underlining the

245 uccessful TAVR program is integration of the heart valve team.

246 f homologous transcatheter tissue-engineered heart valves (TEHVs) was evaluated up to 24 weeks as pul

247 design of next-generation tissue-engineered heart valves (TEHVs) with repair, remodelling and regene

248 fined by infection of a native or prosthetic heart valve, the endocardial surface, or an indwelling c

249 ry of the latest generation of transcatheter heart valve, the SAPIEN 3 (Edwards Lifesciences, Irvine,

250 Furthermore, radiation can damage the heart valves, the conduction system, and pericardium, wh

251 With the rapid evolution of transcatheter heart valve therapies, the feasibility and safety of imp

252 disease for many decades, but transcatheter heart valve therapy has revolutionized the field in the

253 AV with the balloon-expandable transcatheter heart valve (THV) (n = 48) or self-expandable THV (n = 9

254 requires stricter criteria for transcatheter heart valve (THV) approval, including randomized, clinic

255 and efficacy of the CoreValve transcatheter heart valve (THV) for the treatment of severe aortic ste

256 ography is performed to assess transcatheter heart valve (THV) function.

257 The CENTERA transcatheter heart valve (THV) is a low-profile, self-expanding nitin

258 Differences between transcatheter heart valve (THV) size and MDCT measures of annular size

259 or determining the appropriate transcatheter heart valve (THV) size in patients with severe aortic st

260 rmine whether patient-specific transcatheter heart valve (THV) sizing and positioning might improve c

261 ortic annulus is important for transcatheter heart valve (THV) sizing.

262 ext-generation, self-expanding transcatheter heart valve (THV) system in patients with severe symptom

263 aphic follow-up, the advent of transcatheter heart valve (THV) technologies coupled with the highly s

264 s, and predisposing factors of transcatheter heart valve (THV) thrombosis following transcatheter aor

265 Transcatheter heart valve (THV) thrombosis has been increasingly repor

266 ence, timing, and treatment of transcatheter heart valve (THV) thrombosis.

267 New generation transcatheter heart valves (THV) may improve clinical outcomes of tran

268 erexpanding balloon-expandable transcatheter heart valves (THV) when excessive oversizing is a concer

269 e implantation using different transcatheter heart valves (THV).

270 bust data on the durability of transcatheter heart valves (THVs) are limited.

271 ding Evolut PRO or Evolut PRO+ transcatheter heart valves (THVs) may cause coronary occlusion during

272 (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after trans

273 ons of currently available valve prosthesis, heart valve tissue engineering has emerged as a promisin

274 We discuss the various concepts of heart valve tissue engineering underlying the design of

275 ew provides a brief overview of the field of heart valve tissue engineering, with emphasis on recent

276 of biological reagents to guide and regulate heart valve tissue engineering.

277 enselae, and Coxiella burnetii from surgical heart valve tissue specimens with an analytic sensitivit

278 present in formalin-fixed, paraffin-embedded heart valve tissue.

279 ls for correctively engineering age-specific heart valve tissues.

280 Blood circulation is dependent on heart valves to direct blood flow through the heart and

281 h balloon- and self-expandable transcatheter heart valves to transfemoral transcatheter aortic valve

282 mendous technical evolution of transcatheter heart valves, to date, the clinically available heart va

283 etting, two-thirds of SAPIEN 3 transcatheter heart valve treated transcatheter aortic valve implantat

284 tral valve stenosis or prosthetic mechanical heart valves, treatment options include vitamin K antago

285 not only the size but also the transcatheter heart valve type (self-expanding vs. balloon-expandable)

286 and P30 murine aortic (AoV) and mitral (MV) heart valves uncovered distinct subsets of melanocytes,

287 ning connective tissue homeostasis in mature heart valves using in vivo and in vitro approaches.

288 se of dabigatran in patients with mechanical heart valves was associated with increased rates of thro

289 on) and changes in regurgitant grade at each heart valve were evaluated.

290 Therefore, developing heart valves were examined to determine if NFATc1 functi

291 rate to severe mitral stenosis or mechanical heart valves were excluded from the trial.

292 Heart valves were primary sites for ERE activation by BP

293 ycosaminoglycans that are exposed on injured heart valves, where bacteria attach and form vegetations

294 mechanical anisotropy in the MVAL and other heart valves, which is essential to heart valve function

295 l outcomes in pregnant women with mechanical heart valves who received different methods of anticoagu

296 nplace to safely replace damaged or diseased heart valves with mechanical and biological prostheses.

297 imitations, the concept of tissue engineered heart valves with self-repair capacity has been introduc

298 s for management of patients with prosthetic heart valves with the 2017 European Society of Cardiolog

299 ity and safety of implanting a transcatheter heart valve within a failed tissue valve has been establ

300 n of the device, intended performance of the heart valve without moderate or severe regurgitation, an